An Efficacy and Safety Study of JNJ-56021927 (Apalutamide) in High-risk Prostate Cancer Subjects Receiving Primary Radiation Therapy: ATLAS (NCT02531516)
ATLAS: A Randomized, Double-blind, Placebo-controlled Phase 3 Study of JNJ-56021927 in Subjects With High-risk, Localized or Locally Advanced Prostate Cancer Receiving Treatment With Primary Radiation Therapy
🩺 Plain-English Summary (8th-Grade Level)
The purpose of this study is to determine if apalutamide plus gonadotropin releasing hormone (GnRH) agonist in participants with high-risk, localized or locally advanced prostate cancer receiving primary radiation therapy (RT) results in an improvement of metastasis-free survival (MFS) based on conventional imaging assessed by blinded independent central review (BICR).
Who can join: Review the eligibility criteria below.
Location: Clinical Research Facility — Homewood, Alabama
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (263 Sites)
Showing the first 25 of 263 sites.
- Clinical Research Facility — Homewood, Alabama
- Clinical Research Facility — Chandler, Arizona
- Clinical Research Facility — Scottsdale, Arizona
- Clinical Research Facility — Tucson, Arizona
- Clinical Research Facility — Bakersfield, California
- Clinical Research Facility — Los Angeles, California
- Clinical Research Facility — Orange, California
- Clinical Research Facility — San Bernardino, California
- Clinical Research Facility — San Diego, California
- Clinical Research Facility — San Francisco, California
- Clinical Research Facility — Aurora, Colorado
- Clinical Research Facility — Denver, Colorado
- Clinical Research Facility — Middlebury, Connecticut
- Clinical Research Facility — Bradenton, Florida
- Clinical Research Facility — Daytona Beach, Florida
- Clinical Research Facility — Fort Myers, Florida
- Clinical Research Facility — Hialeah, Florida
- Clinical Research Facility — Lakewood Rch, Florida
- Clinical Research Facility — Naples, Florida
- Clinical Research Facility — Plantation, Florida
- Clinical Research Facility — Meridian, Idaho
- Clinical Research Facility — Evergreen Park, Illinois
- Clinical Research Facility — Harvey, Illinois
- Clinical Research Facility — Jeffersonville, Indiana
- Clinical Research Facility — Wichita, Kansas
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Prostatic Neoplasms
- A Study of JNJ-69086420, an Actinium-225-Labeled Antibody Targeting Human Kallikrein-2 (hK2) for Advanced Prostate Cancer — Phoenix, Arizona
- PSMA PET/CT for Assessment of Recurrent Prostate Cancer — Vancouver, British Columbia
- A Study of JNJ-56021927 (ARN-509) and Abiraterone Acetate in Participants With Metastatic Castration-Resistant Prostate Cancer — Los Angeles, California
- Contributions of a Paramedical Approach in the Prevention and Treatment of Side Effects Associated With Radical Prostatectomy — Fort-de-France,
- A Study of Apalutamide (ARN-509) in Men With Non-Metastatic Castration-Resistant Prostate Cancer — Birmingham, Alabama
Explore by condition: All Prostatic Neoplasms clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Review the official NIH record below to find the coordinating site.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.